Vicapsys Life Sciences, Inc. (VICP)

0.4440 -0.5459 (-55.15%) As of 09:37AM EDT. Market open.

Vicapsys Life Sciences, Inc.

7778 Mcginnis Ferry Road
Suite 270
Suwanee, GA 30024
United States
972 891 8033
https://vicapsys.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 2

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Federico Pier	CEO, Executive Chairman & Interim President	120k	N/A	1968
Mr. Jeffery Wright CPA, CPA	Chief Financial Officer	90k	N/A	1983
Dr. Mark C. Poznansky M.D., Ph.D.	Chief Scientist Advisor & Founder	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Vicapsys Life Sciences, Inc. focuses on the development and commercialization of VICAPSYN, a proprietary product. The company's product is applied to transplantation therapies and related stem-cell applications in the transplantation field. It also develops VYBRIN, a product based on CXCL12 for prevention of post-surgical adhesions in abdominal surgery, coating of implantable medical devices and other implants to eliminate fibrosis, and wound healing with a focus on diabetic ulcers. The company was formerly known as Phage Therapeutics International, Inc. and changed its name to Vicapsys Life Sciences, Inc. in September 2017. Vicapsys Life Sciences, Inc. was incorporated in 1997 and is based in Suwanee, Georgia.

Corporate governance

Vicapsys Life Sciences, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.